Experiment 688651
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Urtica dioica (URTICACEAE) |
| Citation | LOWE,FC: FAGELMAN,E:. (1999). PHYTOTHERAPY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: AN UPDATE.. 53(4) |
| Amount utilized | |
| Compound isolated | |
| Disease | PROSTAGLUTT FORTE (COMBINATION OF S. REPENS AND U. DIOICA) WERE RECENTLY REPORTED. THE RANDOMIZED, PLACEBO-CONTROLLED STUDY INCLUDED ONLY 20 PATIENTS IN EACH ARM. AFTER A 2 WEEK PLACEBO LEAD-IN PERIOD, THERE WAS 6 MONTHS OF DOUBLE-BLIND TREATMENT. IN THAT STUDY, BOTH IPSS AND PEAK FLOW RATE SHOWED GREATER IMPROVEMENT WITH TREATMENT THAN WITH PLACEBO. THE IPSS WENT FROM 18.6 DOWN TO 11.1 WITH PROSTAGLUTT AND FROM 19 TO 17.6 WITH PLACEBO (P=0.002). DURING THE OPEN-LABEL EXTENSION PLACEBO GROUP IMPROVED FROM 17.6 TO 13.3; SURPRISINGLY, THE PROSTAGLUTT-TREATED GROUP ALSO CONTINUED TO IMPROVE, DROPPING FORM 11.1 TO 9.8. IN TERMS OF PEAK FLOW RATES, THE PROSTAGLUTT-TREATED PATIENTS IMPROED BY 2.3 ML/S OVER THE FIRST 6 MONTHS AND BY AN ADDITIONAL 1.15 ML/S OVER THE OPEN-LABEL SECOND 6 MONTH PERIOD. THE PLACEBO GROUP SHOWED MINIMAL CHANGE DURING THE INITAL PLACEBO PERIOD (O.45 ML/S); HOWEVER, DURING ACTIVE TREATMENT THERE WAS A 2-ML/S IMPROVEMENT. THUS, THIS STUDY INDICATED THAT FURTHER IMPROVEMENT WITH PROSTAGLUTT THERAPY CAN BE ACHIEVED WITH LONGER TREATMENT (FROM 6 TO 12 MONTHS). THIS FINDING FURTHER SUPPORTS THE NEED FOR DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF AT LEAST 1 YEAR IN DURATION TO EVALUATE PLANT EXTRACT THERAPY. |
| Number | 4 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Extract | TYPE EXT NOT STATED |
| Gender | MALE |